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Cost-effectiveness analysis is a widely used method for deter- 
mining the value of a health intervention. It seeks to determine 
the cost-effectiveness ratio, or the dollar cost per unit improve- 
ment in health obtained by a specific health intervention, in
comparison with a well defined alternative intervention (1,2). 
Cost-effectiveness analysis erves as an aid in selecting the 
clinical strategies that lead to the greatest health improve- 
ments for a given expenditure. It does so by estimating both the 
costs and health effects of alternative strategies , making ex- 
plicit the dollar and health tradeoffs involved. Because these 
tradeoffs are ubiquitous within health care, affecting physi- 
cians, hospitals, health care systems, insurers, government 
programs and patients, cost-effectiveness analysis has gained 
wider use and is beginning to be used in some parts of the 
world as a means of deciding which drugs and other treatments 
are made available under national health plans. In the United 
States, the method is used to inform clinical guidelines and to 
market drugs and other forms of therapy; it is likely to be used 
increasingly in making decisions about insurance coverage. 
Cost-effectiveness analysis is a method of considering both 
the effectiveness of an intervention and its cost. One major 
importance of cost-effectiveness i  that it emphasizes the 
relevance of both components of the ratio and ensures that 
both effectiveness and cost are considered in clinical decision 
making. 
The cost-effectiveness ratio is defined as the difference in 
costs between two interventions, divided by the difference in 
effectiveness, defined as years of life or quality-adjusted life 
years (QALYs): 
Cost2 - Cost 1 
CE2 1 = QALY  2 _ QALY I  ' 
Cost-effectiveness analysis should be distinguished from 
cost-benefit analysis. In cost-effectiveness analysis, the costs 
are commonly expressed in monetary terms, whereas the 
effectiveness is expressed as a health benefit, such as years of 
life saved or quality-adjusted years of life saved. By compari- 
son, in cost-benefit analysis, both costs and benefits are ex- 
pressed in the same terms, usually in dollars. 
Cost-effectiveness analysis is a useful way to express the 
potential benefit o be gained from a particular investment. 
Because programs rarely save both costs and lives, the relative 
benefit achieved from one investment can be compared with 
what would be expected from another investment. Cost- 
effectiveness analysis is also a useful way for health planners to 
determine the maximal benefit hat could be gained from a 
given amount of funds or to determine the lowest cost way to 
achieve a desired level of effectiveness. The method cannot 
find the greatest possible benefit for the lowest possible cost, 
because both cannot be obtained simultaneously. 
Because a cost-effectiveness ratio is determined by dividing 
the change in total cost by the change in total health effective- 
ness, the same ratio may be obtained for programs with 
markedly different total costs and total benefits, provided that 
the ratios are the same. Thus, from a health policy perspective, 
it is important o understand not only the relative cost- 
effectiveness of an intervention, but also the total investment 
that would be required if it were to be applied to the target 
population. 
Because cost-effectiveness analyses are driven by the valid- 
ity of the assumptions on which their calculations are based, 
most analyses include a "sensitivity analysis," in which esti- 
mates are repeated using differing assumptions. If the message 
of the analysis is unchanged using reasonable variations in the 
relevant estimates, the reader can be more confident in the 
accuracy of its results. 
Several additional issues must be addressed in any cost- 
effectiveness analysis. These include the perspective of the 
analysis, the alternatives to be compared, the measurement of 
health outcomes and the measurement of costs. 
Perspective of the Analysis 
To determine which costs should be included in a cost- 
effectiveness analysis, it is essential to describe at the outset 
whose perspective is being used; in other words, whose costs 
matter? An analysis conducted from the perspective of an 
individual patient who has traditional (indemnity-type) health 
insurance might incorporate only the costs that the patient 
bears directly, such as a 20% or even smaller copayment. An 
analysis conducted from the perspective of an insurer would 
include the insurance payments hat the patient does not bear 
and would ignore the out-of-pocket payments. Neither of these 
JACC Vol. 27, No. 5 GOLDMAN ET AL. 1021 
April 1996:964-1047 TASK FORCE 6 
approaches incorporates all of the resources used to treat he 
patient. The most widely used and accepted perspective for 
conducting cost-effectiveness analysis is the societal perspec- 
tive, which includes all costs and which avoids double counting. 
For example, disability insurance payments represent transfers 
from an insurer to the disabled claimant. Although the costs of 
administering such insurance are genuine costs, the transfer 
from the insurer to the patient is a cost to one and a benefit o 
the other, and should not be incorporated as a cost in an 
analysis conducted from the societal perspective. 
Specifying the Alternatives 
Every cost-effectiveness analysis implicitly or explicitly in- 
corporates a comparison between two alternatives, with the 
expectation that the better option can then be compared with 
another until the best option has been described. The first 
alternative, and usually the one that motivates the analysis, is 
the intervention under study; it may be the use of a cholesterol- 
lowering drug, it may be sigmoidoscopy asa screening test for 
colon cancer, or it may be cardiac catheterization i  an 
individual who has chest pain. The cost-effectiveness of any 
intervention depends crucially on the alternatives with which 
it is compared. One possible alternative is to "do nothing"; 
another is standard therapy. The former is an appropriate 
alternative only if it in fact represents a commonly used or 
otherwise justifiable approach. If we wish to consider the 
cost-effectiveness of coronary bypass urgery in patients with 
angina and three-vessel coronary artery disease, a cost- 
effectiveness analysis that compares bypass urgery with "do 
nothing" would not be informative, insofar as we believe that 
any symptomatic patient with documented coronary artery 
disease would be treated with drugs or an alternative r vascu- 
larization procedure. 
Once the intervention and the alternative have been se- 
lected, it should be recognized that the numerator of the 
cost-effectiveness ratio, which is described in greater detail 
later, is the difference in costs between the two interventions, 
not the cost of the intervention under primary consideration 
by itself. Similarly, the denominator f the cost-effectiveness 
ratio is the difference in health effects between the intervention 
and the alternative. Thus, cost-effectiveness analysis is always 
comparative, in the sense that the numerator consists of the 
amount by which the health care costs of patients receiving 
the intervention differs from the costs of patients receiving the 
alternative, and the denominator consists of the amount by 
which the intervention changes the health outcome. 
Measuring Health Effects 
To he useful, cost-effectiveness analysis must include a 
measure of health effects or health outcomes based on the 
aspects of health that patients care about. Thus, for example, 
the effectiveness measure ordinarily should not be the cost per 
positive test (for a diagnostic or screening test) or the cost per 
unit change in blood pressure, unless there is a direct link 
between these intermediate outcomes and "final outcome." 
Furthermore, the measures hould be sutticiently global to 
make it possible to compare different kinds of health interven- 
tions and sufficiently sensitive as a measurement i strument to
capture changes in health that patients can detect and lead to 
an appreciable improvement i  their quality of life Or sense of 
well-being. Traditionally, the most widely used global health 
outcome measure had been life expectancy, which is readily 
measured, easily interpreted and can be used to compare a 
wide range of interventions. The major drawback of using life 
expectancy as the only outcome measure is that it does not 
account for any changes in the quality of life. Particularly for 
interventions that relieve pain or improve functional status, life 
expectancy is an inadequate measure of health effects. 
The outcome measure that has gained the greatest accep- 
tance, at least on a conceptual level, is quality-adjusted life 
years or, as it is sometimes called, quality-adjusted life expect- 
ancy. This measure is analogous to life expectancy but gives 
less "credit" to years of life that are spent in pain, impaired 
health or diminished function. An intervention that improves 
quality of life can generate an increase in quality-adjusted life 
years, even if it has no effect on the duration of survival. 
Similarly, an intervention that lengthens life produces more 
quality-adjusted life years if it maintains or improves quality of 
life than if it adds years of life that are impaired by significant 
morbidity. A large literature discusses alternative measures 
of quality of life that can be incorporated into the quality- 
adjusted life year measure, and although there is not yet 
consensus about he best measure of quality-adjusted life years 
to use, there is widespread agreement that it is conceptually 
appropriate operform the quality adjustment and use quality- 
adjusted life years, or something akin to quality-adjusted life 
years, as an outcome measure in cost-effectiveness studies. 
In the calculation of effectiveness, both the risks and 
benefits of the intervention must be considered. For example, 
the potential side effects of aspirin may outweigh its benefits in 
patients who are at low risk for ischemic vascular disease but at 
higher isk for intracerebral or gastrointestinal bleeding. Ob- 
viously an intervention will become less attractive from a 
cost-effectiveness standpoint if, in the overall population or in 
identifiable subgroups, its risks largely or fully counterbalance 
its benefits. 
Measuring Costs 
All cost-effectiveness analyses of medical treatments gener- 
ally include any direct medical costs related to the diagnosis 
and treatment of the disease under question as well as any 
disease-specific costs that may be induced or averted. For 
example, a cost-effectiveness analysis of cholesterol reduction 
must include the cost of the therapy and consider any cardiac- 
related costs that may be avoided or added. Many analyses also 
include other medical costs unrelated to the specific disease in 
question. In the preceding example, such costs might include 
the cost of cancer or stroke in patients whose fatal heart 
disease was averted because of cholesterol reduction. More 
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complicated and controversial nalyses also include costs that 
are not purely medical, such as the cost of nursing home care 
for an elderly person whose life was prolonged because of 
cholesterol reduction. Even more controversial are analyses 
that include calculations for lost earnings, lost opportunities or
societal transfers, uch as social security or disability payments. 
Many health care institutions are developing sophisticated 
cost-accounting methodologies that attempt o assign unit 
costs rather than charges to individual services. In the calcu- 
lation of medical costs, it is sometimes quite difficult to 
distinguish fixed costs, which do not depend on the volume of 
services, from variable costs, which may be critically dependent 
on volume and diminish for the marginal case. 
Discounting 
In cost-effectiveness analysis, costs and benefits in the 
future are not as highly valued as costs or benefits that may be 
realized immediately. To adjust for the diminished value of 
future costs and benefits, analyses use the principle of dis- 
counting. In addition to recognizing the preference to post- 
pone costs but realize the benefit immediately, discounting also 
takes into account the possibility that other diseases or medical 
breakthroughs may intervene and partially or fully negate the 
expected future benefit from the screening or preventive 
intervention. Although a substantial theoretical literature has 
debated whether the discount rate should be linked to the rate 
of monetary inflation, analyses generally discount future costs 
and benefits by about 3% to 5% per year. The principle of 
discounting explains why screening and preventive strategies 
can be very costly if the expenses must be borne immediately, 
whereas the benefits may not accrue for many years. 
Cost-Effectiveness of Screening 
Many commonly used screening tests and procedures are 
inexpensive, yet the total cost of a screening program includes 
not only the initial screening test, but all the costs induced by 
the actions that follow a test result. The first recommendations 
of the Adult Treatment Panel of the National Cholesterol 
Education Program, for example, called for all adults to 
undergo testing with a total blood cholesterol level once every 
5 years. The per-person cost of such testing is quite modest. 
However, individuals found to have an undesirably high blood 
cholesterol level, according to these recommendations, would 
undergo further testing, detailed evaluation and, for those 
deemed to be at high risk, dietary counseling and, in some 
cases, treatment with drugs. Although each step of this cascade 
of management i volves fewer and fewer people, the costs 
typically rise. For example, for the first recommendation of the 
original National Cholesterol Education Program's Adult 
Treatment Panel Cholesterol Guidelines, the screening tests 
themselves would account for approximately one-fortieth of 
the entire costs of implementing the program. Thus, even 
though every participant in a screening program generates 
costs from the initial screening tests, the costs of treating the 
minority who need drugs account for most of the costs of the 
screening program (3). 
Treatment also plays a crucial role in the cost-effectiveness 
of the screening program. The cost-effectiveness of creening 
for any risk factor or occult disease is closely related to the 
cost-effectiveness of its treatment. Typically, cost-effectiveness 
analyses of treatment assume that the individuals with the risk 
factor or disease (i.e., the candidates for treatment) have 
already been identified. All efforts and associated costs of 
identifying them were incurred in the past, and are no longer 
relevant to the treatment decision. However, those costs are 
central to analyzing the cost-effectiveness of screening pro- 
grams, which begin with the process of identifying such in- 
dividuals. The cost-effectiveness of a screening program is 
limited by the cost-effectiveness of subsequent treatment; 
ordinarily all of the benefits of screening result from the 
treatment, sothere are no additional benefits from the screen- 
ing program, yet screening itself imposes costs that are ignored 
in an analysis of treatment. If treating a person with a known 
cholesterol level is not cost-effective, it cannot be cost-effective 
to screen that person. 
The cost-effectiveness of screening depends on several 
factors besides the cost-effectiveness of treatment. These fac- 
tors include the test's ability to discriminate between people 
who do and do not have the disease or risk factor (sensitivity 
and specificity), the cost of the test as well as any risks or health 
benefits directly resulting from the testing procedure (which 
are negligible for many screening tests) (4,5). 
The estimation of costs is, by definition, subject o uncer- 
tainties and future changes. For example, medications may 
become less expensive when their patents expire, if and when 
the availability of multiple medications in the same class 
provides price competition, or if large purchasers can demand 
lower prices. Reductions inthe costs of cardiac are, driven by 
managed care and competition, may actually make prevention 
somewhat less attractive conomically since future savings, 
generated by avoiding or delaying future events, are reduced. 
Influence of Other Risk Factors on the 
Costs and Benefits of Risk Reduction 
The cost-effectiveness of risk factor modification is ex- 
tremely sensitive to the presence of known coronary heart dis- 
ease or other risk factors. For instance, the cost-effectiveness 
ratios of secondary prevention are usually forecasted to be 
superior to those of primary prevention. Individuals with 
preexisting disease have a substantially increased risk of dying 
from coronary disease compared with those without coronary 
heart disease (6,7). Accordingly, the short-term benefits of 
modifying one or more risk factors hould be associated with a 
greater absolute risk reduction in secondary prevention com- 
pared with primary prevention. The presence of coronary heart 
disease also significantly decreases one's life expectancy. 
Therefore, the time horizon for therapy isshortened, resulting 
in lower costs associated with risk factor modification for 
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Table 1. Example of Costs, Effectiveness and Cost-Effectiveness for 
a Hypothetical Intervention in 10,000 Patients for 5 Years* (high 
risk patients versus low risk patients) 
High Risk Low Risk 
Untreated Treated Untreated Treated 
Annual death rate 10% 5% 1% 0.5% 
Yr of life savedt 0 5,209 0 614 
Cost of treatment 0 90.5 0 99.0 
($ millions) at $2,000/yr 
Annual CABG rate 6% 3% 0.6% 0.3% 
Cost/CABG $20,000 $20,000 $20,000 $20,000 
Annual MI rate 4% 2% 0.4% 0.2% 
Cost/MI $10,000 $10,000 $10,000 $10,000 
Annual rate of other events 4% 2% 0.4% 0.2% 
Cost/other event $5,000 $5,000 $5,000 $5,000 
Medical costs ($ millions) 70.0 39.7 8.8 4.4 
Total cost ($ millions) 70.0 130.2 8.8 103.4 
Total cost difference 60.2 94.8 
($ millions) 
Approximate cost/yr $11,500 $155,000 
of life saved 
*Simplified so that the intervention reduces all risks by 50%, neither costs 
nor health effects discounted, all patients are assumed to die at midyear, and the 
analysis considers only the first 5 years, tBy life-table analysis. CABG = coronary 
artery bypass graft surgery; MI = myocardial infarction. 
secondary versus primary prevention. All other things being 
equal, secondary prevention should be associated with greater 
short-term benefits and lower long-term costs, resulting in 
superior cost-effectiveness ratios compared with primary pre- 
vention. As more and more sensitive measures are found to 
identify currently preclinical coronary artery disease, the risk 
of future events and hence the cost-effectiveness of treatments 
can be expected to be somewhere inbetween current forecasts 
for secondary and primary prevention. 
The overall effectiveness of an intervention is generally 
greater in high risk patients because 
Absolute risk reduction = Underlying risk 
× Relative risk reduction. 
These principles can be illustrated by a hypothetical example. 
Suppose an intervention can be given to either high or low risk 
patients, at a cost of $2,000/year for 5 years. If the drug reduces 
death and cardiac events by 50%, its cost-effectiveness depends 
on the underlying (or baseline) risk in the population being 
treated (Table 1). To illustrate this principle, Goldman et al. 
(8) estimated the cost-effectiveness of HMG-CoA reductase 
inhibition for primary and secondary prevention of coronary 
heart disease. When used for secondary prevention, 20 mg/day 
of lovastatin was estimated to save lives and money in younger 
men with cholesterol levels above 250 mg/dl, and to be 
cost-effective for all other patients except young women with 
cholesterol levels below 250 mg/dl. However, in primary pre- 
vention, favorable cost-effectiveness ratios were forecasted 
only for select subgroups among whom cholesterol levels were 
extremely high, such as in patients with heterozygous familial 
hypercholesterolemia (9), or in whom very high (usually above 
300 mg/dl) cholesterol levels were accompanied by other 
coronary risk factors. 
The presence of multiple risk factors for coronary disease 
also makes the cost-effectiveness ratios of risk factor modifi- 
cation more favorable for reasons imilar to those described in 
secondary prevention. Multiple risk factors place an individual 
at high absolute risk of coronary events, so modification of any 
one risk factor (i.e., cigarette smoking, hyperlipidemia, hyper- 
tension) is therefore associated with a greater decrease in 
absolute coronary risk. For instance, Hamilton et al. (10) 
estimated that lipid modification among Canadian adults with 
pretreatment cholesterol levels above the 90th percentile of 
the U.S. distribution in this age group would cost $34,000 (in 
1993 U.S. dollars) per year of life saved among low risk men 
compared with $16,000 among high risk men who smoke 
cigarettes and have hypertension. These results were consistent 
with those of Goldman et al. (8), where lipid modification 
among American men 45 to 54 years old with pretreatment 
cholesterol levels of 300 mg/dl or higher would cost about 
$130,000 (in 1993 dollars) per year of life saved in the absence 
of coronary risk factors but only about $15,000 in the presence 
of diastolic hypertension, cigarette smoking and obesity. For 
antihypertensive therapy, Lindgren and Persson (11) have 
estimated that heavy cigarette smoking would improve the 
cost-effectiveness ratios of antihypertensive therapy for a 52- 
year old Swedish man by 25% or more. 
It should be emphasized that all of these analyses estimated 
changes in life expectancy based on the multivariate logistic 
equations developed by the Framingham Heart Study (12). 
There remains ome disagreement asto whether or not these 
independent risk factors are multiplicative or additive in 
nature. The cost-effective estimates described assumed the 
multiplicative relationship, which will increase the importance 
of multiple risk factors. 
Hyperlipidemia 
Screening. The cost-effectiveness of cholesterol screening 
is likely to be similar to the cost-effectiveness of treatment 
because treatment, not testing, is responsible for most of the 
costs of cholesterol screening programs (3). Nevertheless, be- 
cause most of the published estimates of the cost-effectiveness 
of treatment excluded the costs of the screening tests, the cost 
per life-year saved for a screening and treatment program are, 
by definition, somewhat higher than the published estimates 
for treatment programs alone. 
Treatment. Among specific modifiable risk factors, hyper- 
lipidemia has been the most comprehensively studied from a 
health economics perspective. The majority of these studies 
draw heavily on the results of the Framingham Heart Study, as 
the benefits associated with lipid modification are usually 
based on these published univariate and multivariate regres- 
sion equations (7,13,14). 
As is standard in cost-effectiveness analysis, the authors 
of studies of cholesterol reduction measured the costs of the 
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intervention (typically a drug or diet), the savings resulting 
from the prevention of myocardial infarction and other man- 
ifestations of coronary heart disease, and the costs of any 
diseases or health conditions that result from treatment. The 
"net costs" of the intervention comprise the numerator of 
the cost-effectiveness ratio; the denominator is the increase 
in the life expectancy that results from treatment. Nearly all 
published studies of the cost-effectiveness of treatment make 
the crucial assumptions that cholesterol reduction reduces 
coronary heart disease incidence and does not increase mor- 
bidity or death from any other causes (15). The cholesterol- 
lowering intervention reduces ome future medical expendi- 
tures and increases life expectancy by preventing coronary 
heart disease. If the assumption that treatment has a negligible 
effect on morbidity and death from other causes is incorrect, 
such studies both underestimate the costs of the intervention 
(by ignoring the costs of treating diseases that the intervention 
promotes) and overestimate the beneficial health effects. 
Overall, the results of these analyses are reasonably similar, 
with more favorable cost-effectiveness ratios forecasted for 
high risk individuals compared with those at low risk (15-18). 
Treatment of hyperlipidemia s also usually predicted to be 
more cost-effective for men than women because of the rela- 
tively higher absolute risk of coronary disease among men, all 
else being equal. 
Weinstein and Stason (19) and Goldman et al. (8,9) have 
published a number of analyses on the cost-effectiveness of 
lipid modification. Early estimates by Weinstein and Stason 
(19) were based on the results of the Lipid Research Clinics 
Trial and focused only on men 45 to 50 years old with a serum 
cholesterol greater than 265 mg/dl. Assuming annual treat- 
ment costs of $2,000 and full compliance, they estimated a cost 
per year of life saved of over $175,000 for cholestyramine in 
1993 dollars. Later work, using the Coronary Heart Disease 
Policy Model, also included the cost savings of preventing 
nonfatal coronary events and estimated the cost-effectiveness 
of HMG-CoA reductase inhibition for primary and secondary 
coronary heart disease prevention (8). Primary prevention i  
men with pretreatment cholesterol levels of 300 mg/dl (7.76 
mmol/liter) or higher was associated with cost-effectiveness 
ratios ranging from about $15,000 to about $350,000 per year 
of life saved in 1993 dollars. The least favorable cost- 
effectiveness ratios were found among young men without 
other risk factors. More favorable cost-effectiveness ratios 
were estimated for middle-aged men 45 to 64 years old with 
multiple risk factors, including hypertension, cigarette smoking 
and obesity. The results for women were substantially higher, 
ranging from about $1.75 million per year of life saved to about 
$40,000 per year of life saved in 1993 dollars. As previously 
mentioned, this analysis also forecast overall cost savings 
associated with secondary prevention i men 35 to 54 years old 
and very favorable cost-effectiveness ratios for most individuals 
with clinically evident coronary disease. 
Oster and Epstein (18) used data from the Lipid Research 
Clinics Trial to estimate the cost-effectiveness of cholesterol 
reduction associated with cholestyramine. Among men 35 to 
74 years old, the cost-effectiveness of lifelong therapy ranged 
from about $95,000 to over $1.75 million per year of life saved 
in 1993 dollars. Younger individuals and those with higher 
pretreatment cholesterol levels had more favorable cost- 
effectiveness ratios. Their analyses also suggested that midterm 
therapy (i.e., 20 years) may be more cost-effective than lifelong 
therapy. Once again, treatment was more cost-effective for 
individuals with multiple risk factors. For instance, the cost- 
effectiveness ratios for men of all ages with smoking, hyper- 
tension and diabetes were less than 50% of the values calcu- 
lated for those who had no additional risk factors other than 
their hyperlipidemia. It should be noted that this study also 
included an estimate of the medical care costs associated with 
noncardiovascular diseases resulting from patients living 
longer. 
Using data from the Lipid Research Clinics Trial, Kinosian 
and Eisenberg (17) estimated the cost-effectiveness of cho- 
lestyramine r sin, colestipol and oat bran. The cost per year of 
life saved was estimated at about $160,000 for cholestyramine 
resin, about $95,000 for colestipol and about $23,000 for oat 
bran (in 1993 dollars) when applied to the Lipid Research 
Clinics Trial cohort (i.e., men, mean age 48 years, pretreatment 
cholesterol greater than 6.85 mmol/liter [265 mg/dl]). Once 
again, cost-effectiveness ratios were more favorable if the 
intervention was targeted only at those individuals with addi- 
tional risk factors. This analysis also estimated a 20% reduc- 
tion in cost-effectiveness ratios for drug therapy when the 
indirect savings associated with lost earnings were considered 
for those who become unemployed as a result of coronary 
disease. 
Hay et al. (16) incorporated the indirect benefits of reduced 
disability days associated with coronary heart disease into their 
economic evaluation of lovastatin for coronary heart disease 
prevention. For this and perhaps other reasons, this anal- 
ysis predicted some of the most favorable cost-effectiveness 
ratios to date, ranging from about $11,000 to $130,000 (in 1993 
dollars) for the average-risk man and from about $40,000 to 
$360,000 for the average-risk woman. The cost-effectiveness 
ratios for high risk individuals were improved to as little as 
about $7,500 per year of life saved for men and about $23,000 
for women. 
The previously described models estimated the benefits of 
reducing total cholesterol, but high density lipoprotein (HDL) 
cholesterol levels could have a substantial impact on the 
cost-effectiveness of lipid modification if the HDL effect is 
taken into account (15). Hamilton et al. (10) recently estimated 
that the cost-effectiveness ratios associated with HMG-CoA 
reductase inhibitors may be improved by approximately 40% if 
the HDL effect is considered. Using 20 mg of lovastatin as an 
example, this study forecast that a 7% increase in HDL, added 
to the expected 17% reduction in total cholesterol, would 
substantially improve the cost-effectiveness of this therapy. For 
instance, for low risk men between the ages of 30 and 70, the 
cost per year of life saved ranged from $50,000 to $170,000 
(1993 dollars) without consideration f the HDL effect. How- 
ever, when the HDL effect was considered, these ratios ira- 
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proved to between $30,000 and $60,000 per year of life. The 
impact of the HDL effect was greatest for elderly individuals 
because of the diminishing relative risk associated with total 
cholesterol in the elderly. 
Given the increasing awareness of the importance ofserum 
lipids as modifiable coronary risk factors, one can anticipate 
continuing economic evaluations in this area. Future studies 
must include validation of statistical models wherever possible. 
For instance, Grover et al. (20) have used clinical trial results 
in one study to validate the accuracy of a primary prevention 
model. Additional work is also required to estimate the in- 
direct cost savings associated with improved productivity 
among those in whom coronary events are presented. Also, 
quality of life assessments should be incorporated into exist- 
ing models to support cost-utility analyses that better capture 
the improvements in mortality and morbidity associated with 
coronary heart disease prevention. 
Hypertension 
Screening. Screening for hypertension is highly cost- 
effective because blood pressure measurement, when done as 
part of an once visit for other purposes or in many other 
settings, is very inexpensive, and treatment of elevated blood 
pressure can be highly cost-effective. Littenberg et al. (21) esti- 
mated that screening cost approximately $18,500 per quality- 
adjusted life-year saved, in 1993 dollars, for men 40 years of 
age; the cost per quality-adjusted life-year was lower for older 
men and higher for women and younger men. 
Hypertension is a particularly appropriate condition for 
screening because itusually causes no symptoms; the screening 
test is simple, safe and convenient; and available treatments 
are both inexpensive and highly effective. Much of the benefit 
of treating high blood pressure comes from improvements in
quality of life, particularly those that result from stroke pre- 
vention, but treatment also reduces mortality. These effects are 
largest among people who have the greatest elevations of 
blood pressure, most of whom can be identified only by blood 
pressure testing. 
Treatment. The cost-effectiveness ratio for the treatment 
of hypertension is generally favorable for men and women of 
all ages. Littenberg et al. (21) estimated that the marginal cost 
per quality-adjusted year of life gained ranged from about 
$33,000 for men at age 20 to about $9,000 for men at age 60 in 
1993 dollars. For women, the cost ranged from about $50,000 
per quality-adjusted year of life at age 20 to about $14,000 at 
age 60. The results of the analysis were dependent on the cost 
of medication but were relatively unaffected by other assump- 
tions in the analysis. 
Using data from the Framingham Heart Study, Weinstein 
and Stason (22) calculated that savings by avoiding strokes and 
coronary events would offset 20% to 25% of the cost of 
treating moderate to severe hypertension and about 15% of 
the cost of treating mild hypertension. Littenberg et al. (21) 
estimated that he cost per year of life saved was about $23,000 
(in 1993 dollars) for moderate to severe hypertension and 
about wice as much for mild hypertension. 
Edelson et al. (23) reported that primary prevention for 
diastolic blood pressures of 95 mm Hg or above without 
coronary heart disease in persons 35 to 60 years old cost about 
$14,000 per year of life saved for propranolol and about 
$20,000 for hydrochlorothiazide in 1993 dollars. Cost- 
effectiveness ratios varied widely for different medications and 
were estimated to range from about $60,000 to $90,000 per 
year of life saved for newer, more expensive medications. 
Smoking 
Cigarette smoking is a strong, consistent risk factor for the 
development of coronary heart disease. Since smoking can be 
completely eliminated, interventions topromote smoking ces- 
sation have greater potential for reducing cardiovascular risk 
than interventions onany other isk factor. Furthermore, since 
smoking is also a strong risk factor for lung and other cancers 
as well as for chronic obstructive lung disease, reduction of 
smoking would be expected to lower both noncardiac and 
cardiac mortality substantially. 
The cardiovascular risk associated with smoking declines 
sharply in the first 6 months after smoking cessation and 
reaches the level of nonsmokers after 1 to 2 years. Risk appears 
to be reduced in both men and women and in both old and 
young patients. Because some of the risk of smoking appears to 
be mediated through enhanced thrombogenicity and coronary 
vasoconstriction, beneficial effects of smoking cessation can be 
expected even in patients with established atherosclerosis. 
Life expectancy appears to be increased substantially in 
patients who quit smoking. Tsevat and co-workers (24) esti- 
mated that a 35-year old smoker would live 2.4 to 2.8 years 
longer if he or she stopped smoking. Taylor and colleagues 
(25), using a different model, estimated that life expectancy 
would be extended by 5.3 years in a 40-year old man who quit 
smoking and by 3.1 years in a 40-year old woman who quit 
smoking. 
The effectiveness of interventions to promote smoking 
cessation is relatively low, since smokers are both addicted to 
nicotine and psychologically dependent on smoking. A meta- 
analysis of various smoking interventions suggested that an 
average of 5.8% (confidence interval 3.2% to 8.4%) more 
patients than control subjects will cease smoking 12 months 
after an intervention program (26). 
Given their relatively modest cost, however, interventions 
against smoking appear very cost-effective. Cummings and 
colleagues (27) calculated that a physician's advice to stop 
smoking had a cost-effectiveness ratio of between about $1,000 
to about $1,400 per year of life saved in men (1993 dollars) and 
between about $1,700 and $3,000 per year of life saved in 
women, depending on the patient's age. These investigators 
estimated that a physician's advice would still be cost-effective 
even with net smoking cessation rates as low as 1% at 1 year 
(their best estimate of the actual effect was 2.7% at 1 year). 
Oster and co-workers (28), in a similar analysis, estimated the 
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cost-effectiveness of nicotine gum to range from about $6,000 
to $9,000 for men and about $9,500 to $13,000 for women, in 
1993 dollars, depending on age. 
Interventions to promote smoking cessation appear to be 
highly cost-effective because of large potential gains in life 
expectancy among individuals who stop smoking. Smoking 
cessation programs are especially worth the cost when aimed at 
persons who already have coronary disease, such as patients 
who have survived a myocardial infarction (29,30). 
Exercise and Cardiac Rehabilitation 
The potential cost-effectiveness of cardiac rehabilitation, 
including exercise, for secondary prevention isbased primarily 
on the estimates of two overview analyses of randomized trials 
in the 1980s (31,32). Using costs and efficacy data from a 
randomized clinical trial of cardiac rehabilitation, Oldridge 
and colleagues (33) completed an economic evaluation of 
cardiac rehabilitation after acute myocardial infarction. Patient 
mortality and morbidity were similar at 1 year between the 
control and intervention groups. However, quality of life, as 
measured by the time tradeoff method, demonstrated that a 
comprehensive cardiac rehabilitation program was associated 
with 0.052 quality-adjusted life years gained during the 1 year 
follow-up period. Given the incremental direct costs of a 
rehabilitation program, this resulted in costs per quality- 
adjusted life year gained of about $10,000. Incorporating 
estimated improvements in longevity from a meta-analysis of
cardiac rehabilitation, the authors also forecast 0.022 addi- 
tional years for cardiac rehabilitation patients over a 3 year 
follow-up period. Combining both reduced mortality over 3 
years and improved quality of life in year 1, the cost per 
quality-adjusted life year gained due to rehabilitation was 
estimated at less than $8,000 in 1993 dollars. 
There is even less sound data on primary prevention, and 
one can only speculate on the potential cost-effectiveness of 
exercise interventions in primary prevention. However, aerobic 
fitness is associated with positive ffects on serum lipids, blood 
pressure, obesity and glucose intolerance (34-38), so the 
potential impact of modifying these multiple risk factors with 
one intervention could be extremely cost-effective. Moreover, 
lack of exercise in and of itself appears to be an independent 
risk factor for coronary disease ven after adjustment for the 
secondary effects of physical fitness on other coronary risk 
factors. 
Estrogen 
The risk of coronary heart disease is very low in women 
until menopause, when it begins to rise progressively with age. 
This observation suggests that endogenous production of 
estrogen may either protect against he development of coro- 
nary atherosclerosis or prevent plaque rupture and coronary 
thrombosis, or both. 
Observational studies comparing women taking postmeno- 
pausal estrogen therapy with control subjects have shown 
striking reductions in the rate of clinical coronary heart 
disease. Interpretation of these findings has been confounded 
by the generally healthier life-styles of women who take 
estrogen, including less smoking, more exercise and greater 
access to medical care. Randomized trials currently under way 
(the Heart Estrogen-Progestin Replacement Study and the 
Women's Health Initiative) will test the hypothesis that hor- 
mone replacement reduces the risk of heart disease in post- 
menopausal women. 
The effect of estrogen replacement on life expectancy is
complex. Hormone therapy appears to reduce the risk of 
osteoporosis and of hip fracture, as well as reduce the risk of 
coronary heart disease. Unfortunately, hormone therapy also 
appears to increase the risk of endometrial cancer and possibly 
breast cancer, although the latter finding remains controver- 
sial. The overall impact on life expectancy therefore depends 
on the balance of potential risks and benefits. Grady and 
colleagues (39) estimated that estrogen therapy in an average 
white 50-year old woman will increase life expectancy by 0.9 
years. The potential benefit was 2.1 years in women with 
established coronary disease and 1.5 years in women at high 
risk for coronary heart disease. Women at high risk for breast 
cancer had less estimated benefit from estrogen therapy, with 
life expectancy increased by only 0.7 years. Thus, potential 
benefits of estrogen therapy vary according to clinical charac- 
teristics. 
Cost-effectiveness analyses of estrogen therapy have been 
performed, but have not incorporated possible effects on 
coronary heart disease (40). Because the greatest potential 
gains in the life expectancy are due to the likely effects of 
estrogen on heart disease, previous cost-effectiveness analyses 
are likely to have underestimated the value of estrogen therapy. 
Aspirin 
Both oral anticoagulants and aspirin have been shown to be 
beneficial for reducing mortality after acute myocardial infarc- 
tion. Based on its efficacy and economics, aspirin appears to be 
associated with favorable cost-effectiveness timates and to be 
the preferred treatment unless a patient cannot olerate it (41). 
Cost-Effectiveness in Perspective 
Cost-effectiveness analysis is intended to improve clinical 
practice and aid in the development of clinical guidelines and 
health policy by providing information about the value of 
alternative health interventions inspecific populations. It is not 
intended to be the sole basis for resource allocation in health 
care because of technical limitations of the method and the 
importance of considerations that are not part of the analysis 
(such as specific social goals and local factors). 
Results of cost-effectiveness analyses are often displayed in 
a comparative format called a "league table" (Table 2). League 
tables run the risk of including studies with differing assump- 
tions. In updating results to a common year, the tables also 
make simplifying assumptions regarding inflation. Neverthe- 
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Table 2. Heart Disease Cost-Effectiveness Overview* 
$/YLS or 
Strategy Condition Patient Targeting Study (ref. no.) Year $/QALYt 
Highly Cost-Effective (<$20,000/YLS or QALY) 
Lovastatin (20 rag/d) Hyperlipidcmia 2 °, chol ->250 rag/all, men 45-54 Goldman et al. (8) 1991 Saves $ and lives 
yr old 
Enalapril EF -<0.35 
Nurse counseling Post-MI 
manual 
Physician counseling 
Beta-blocker 
Lovastatin (20 mg/d) 
PTCA 
CABG 
Advice and nicotine 
gum 
Propranolol 
Usual care 
CABG 
CHF Glick et al. (42) 1994 Saves $ and lives 
Smoking Krumholz et al. (30) 1993 250 
Smoking Men 50-54 yr old Cummings et al. (27) 1989 1,300 
Post-MI High risk Goldman et al. (43) 1987 3,600 
Hyperlipidemia 2 °, chol ->250 mg/dl, women 45- Goldman et al. (8) 1991 4,700 
54 yr old 
Chronic CAD Severe angina, 1 VD~: Wong et ai. (44) 1990 8,700-10,200]" 
Chronic CAD Severe angina, left main disease§ Weinstein and Stason (45) 1982 9,200t 
Smoking Women 50-54 yr old Cummings et al. (27) 1989 13,000 
Hypertension Edelson et al. (23) 1990 16,900 
Hypertension Women 60 yr old Littenberg et al. (2t) 1990 18,000t 
Chronic CAD Mild angina, 3 VDI] Weinstein and Stason (45) 1982 18,2001, 
Relatively Cost-Effective ($20,000-$40,000/YLS or QALY) 
Beta-blocker MI Low risk Goldman et al. (43) 1987 20,200 
Lovastatin (20 rag/d) Hyperlipidemia 1 °, chol ->300 mg/dl, 3 RF, men Goldman et al. (8) 1991 20,200 
55-64 yr old 
Exercise Prophylaxis Men 35 yr old Hatziandreu et al. (46) 1988 22,4001, 
Lovastatin (20 mg/d) Hyperlipidemia 2 °, chol <250 mg/dl, men 55-64 Goldman et al. (8) 1991 22,900 
yr old 
Usual care Hypertension Men 40 yr old Littenberg et al. (21) 1990 23,700~" 
Hydrochlorothiazide Hypertension Edelson et al. (23) 1990 25,400 
Captopril Post-MI EF -<0.40 Tsevat et al. (47) 1995 28,400t 
Community-wide Hypertension DBP ->105 mm Hg Weinstein and Stason (45) 1976 29,700 
screening 
ECG Ex testing CAD CAD, p - 0.60, men 55 yr old Doubilet et al. (48) 1985 30,200t¶ 
Oat bran Hyperlipidemia LRC-CPPT Pt# Kinosian and Eisenberg (17) 1988 31,600 
CCU Possible MI MI, p - 0.50 Fineberg et al. (49)** 1984 35,000 
Angiography CAD CAD, p - 0.90, men 55 yr old Doubilet et al. (48) 1985 37,000t¶ 
ECG Ex testing Asymptomatic Men 60 yr old, ->1 RF Sox et al. (50) 1989 37,700 
Borderline (>$40,000-$60,000) 
Lovastatin (20 mg/d) Hyperlipidemia 1 °, chol ->300 mg/dl, 2 RF, men Goldman et al. (8) 1991 41,800 
55-64 yr old 
Usual care Hypertension DBP 95-104 mm Hg Weinstein and Stason (22) 1976 41,900 
CABG Chronic CAD Severe angina, 2 VDII Weinstein and Stason (45) 1982 42,5001, 
Usual care Hypertension Men 20 yr old Littenberg et al. (21) 1990 42,6001" 
Lovastain (20 mg/d) Hyperlipidemia 2 °, chol <250 mg/dl, women 55- Goldman et al. (8) 1991 48,600 
64 yr old 
Nifedipine Hypertension Edelson et al. (23) 1990 48,900 
Expensive (>$60,000-$100,000/YLS or QALY) 
Usual care Hypertension Women 20 yr old Littenberg et al. (21) 1990 64,500t 
Angiography CAD CAD, p = 0.60, men 55 yr old Doubilet et al. (48) 1985 71,300t¶ 
CABG Chronic CAD Severe angina, 1 VD H Weinstein and Stason (45) 1982 72,900t 
CABG Chronic CAD Mild angina, 2 VDII Weinstein and Stason (45) 1982 72,900t 
Lovastatin (20 mg/d) Hyperlipidemia 1 °, chol ->300 mg/dl, 0 RF, men Goldman et al. (8) 1991 78,300 
55-64 yr old 
CCU Possible MI MI, p = 0.20 Fineberg et al. (49) 1984 88,700 
PTCA Chronic CAD Mild angina, 1 VD (CAD) Wong ct al. (44) 1990 91,5001, 
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Table 2. Continued 
$~fi(LS or 
Strategy Condition Patient Targeting Study (ref. no.) Year $/QALYt 
Expensive (+$75,000/YLS or QALY) 
PTCA Chronic CAD Mild angina, 2 VD Wong et al. (44) 1990 109,000t 
Captopril Hypertension Edelson et al. (23) 1990 111,600 
Cholestyramine bulk Hyperlipidemia LRC-CPPT Pt# Kinosian and Eisenberg (18) 1988 115,500 
drug 
Cholestyramine Hyperlipidemia Chol 315 mg/dl, 45-49 yr old Oster and Epstein (17) 1987 122,100 
ECG Ex testing Asymptomatic Men 40 yr old Sox et al. (50) 1989 124,400 
Lovastatin (20 rag/d) Hyperlipidemia 1 °, chol ->300 mg/dl, 0 RF, Goldman et al. (8) 1991 148,500 
men 45-54 yr old 
CCU Possible MI MI, p - 0A0 Fineberg et al. (49) 1984 177,400 
CCU Possible MI MI, p = 0.05 Fineberg et al. (49) 1984 373,800 
CABG Chronic CAD Mild angina, 1 VDII Weinstein and Stason (45) 1982 1,142,000t 
Cholestyramine Hyperlipidemia Chol 315 mg/dl, 60-65 yr old Oster and Epstein (51) 1987 1,055,000 
Lovastatin (20 mg/d) Hyperlipidemia 1 °, chol ->300 mg/dl, 0 RF, Goldman et al. (8) 1991 2,024,800 
women 35-44 yr old 
*Adapted with permission from Kupersmith J, Holmes-Rovner M,Hogan A, Rovner D, Gardiner J. Cost-effectiveness analyses inheart disease: ischemia, congestive h art 
failure, and arrhythmias. Prog Cardiovasc Dis 1995;37:307-48. tAll values have been updated to 1993 $; values with a dagger are shown in dollars per quality-adjusted lifeyears 
($/QALY); those without a dagger are in dollars per year of life saved ($/YLS). :~Fifty-five y ar old men with type A lesions and normal ventricular function. §Saves both money 
and lives or quality-adjusted lifeyears. I]Analysis was of 55-year old man; ejection fraction (EF) ->0.40. #Lipid Research Clinics Trial-Coronary Primary Prevention Trial 
(LRC-CPPT), patients were men (average age 48 years), 38% smokers, cholesterol ->265 mg/dl, ow density lipoprotein ->190 mg/dl. ¶Minimal willingness topay; interventional 
strategy was coronary artery bypass graft surgery (CABG); percutaneous transluminal coronary angioplasty (PTCA) was not considered. **Fineberg et al. (49) data recalculated 
by Weinstein and Stason (19). CAD = coronary artery disease; CCU = coronary care unit; CHF = congestive h art failure; Chol = pretreatment cholesterol; d = day; DBP = 
diastolic blood pressure; ECG = electrocardiographic; Ex =exercise; MI = myocardial infarction; Pt = patient; ref - reference; RF = other isk factors; VD - vessel disease. 
1 ° = primary prevention; 2 ° = secondary prevention. 
less, league tables can provide a useful general approach. In 
such tables, the interventions are often ranked in terms of the 
cost per unit of effectiveness (usually ears of life or quality- 
adjusted life years saved). 
It is appealing to choose adollar threshold for intervention; 
interventions whose cost-effectiveness ratio is less than this 
figure would be considered acceptable values, whereas those 
with greater cost-effectiveness ratios would be considered too 
expensive. Some interventions, uch as therapy with inexpen- 
sive antihypertensive drugs, are cost-effective in nearly every 
population studied. Many other interventions are highly cost- 
effective in some but not all individuals with the targeted 
condition. For example, as Table 2 illustrates, low dose lova- 
statin is cost-saving when administered to middle-aged male 
survivors of myocardial infarction; costs about $4,700 per year 
of life saved when administered tomiddle-aged female survi- 
vors of myocardial infarction; and costs more than $2,000,000 
per year of life saved when used for primary prevention in 
young women with hypercholesterolemia. 
Although such tables provide useful information, their 
interpretation must recognize the characteristics and compa- 
rability of the studies on which they are based. Because league 
tables usually draw from multiple published studies, it is 
important to ensure that the components of the studies, as 
presented in the table, are comparable. 
Studies commonly differ in the ways they measure costs and 
effectiveness, the way in which the intervention is defined and 
applied, assumptions about he underlying health care system 
into which the intervention is integrated and the population 
under study. The manner in which costs are measured (e.g., 
generated from charge data, actual payments or formulas 
designed to estimate "true" costs; comprehensiveness in in- 
cluding all appropriate costs; method for projecting future 
costs and adjusting for inflation) may differ among studies. 
Similarly, the units of effectiveness may vary (e.g., life expect- 
ancy, quality-adjusted life years or a more limited outcome, 
such as number of lives saved or test result). Even among 
studies that use quality-adjusted life years, the method for 
measuring quality of life may vary, with significant conse- 
quences for the estimated effectiveness of the intervention. 
Studies may also vary markedly in the extent o which they 
have performed sensitivity analyses to confirm the reliability of 
their conclusions. League tables constructed with attention to 
such considerations are most likely to be useful in estimating 
the relative value of alternative medical interventions. 
The rare interventions that save costs as well as years of life 
obviously should be adopted, but most interventions represent 
a true financial investment to yield health rather than eco- 
nomic benefits. Some investigators have proposed that if the 
cost per year of life (or quality adjusted year of life) is less than 
about $20,000, the intervention is generally considered very 
cost effective, whereas progressively more costly interventions 
are less and less attractive. At the current ime, programs that 
cost less than about $40,000 per year of life saved, which 
roughly correspond to renal dialysis, have been recommended 
by some authors. Conversely, at costs above about $75,000 per 
year of life saved, we find it difficult to generate nthusiasm 
for an intervention unless there are reasons to believe the 
analysis is not sufficiently comprehensive to represent the 
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clinical decision adequately. For intermediate-range costs, it is 
difficult o be prescriptive. 
Conclusions 
Based on these general guidelines, programs for smoking 
cessation, screening and treating hypertension, especially with 
low cost medications, and secondary prevention with aspirin 
and cholesterol-lowering are recommended. Cholesterol re- 
duction for primary prevention is more problematic, with 
current analyses uggesting that it be targeted to patients 
whose risk is substantially elevated because of additional risk 
factors or markedly elevated cholesterol levels, and that lower 
cost medications be emphasized. Comprehensive cardiac reha- 
bilitation after a myocardial infarction may also be worthwhile 
from a cost-effectiveness standpoint, although its incremental 
value when added to other cost-effective treatments i  not 
certain. 
The cost-effectiveness of a medical intervention depends 
not only on its inherent characteristics but also on the patients 
to whom it is applied. Cost-effectiveness ratios describe an 
interaction between an intervention and a patient. In the 
evaluation of specific strategies, the following issues hould be 
considered: 
1. What is the expected impact of an intervention on mortality 
and quality of life? 
2. How high arc the costs of the strategy compared with 
alternatives? Will these costs be offset by economic savings 
due to delays or prevention of adverse outcomes? 
3. What is the time frame in which the costs and benefits are 
expected to occur? 
4. How likely is your patient o adhere to the recommended 
therapy? 
As reflected in research described in this task force, effec- 
tive interventions that are well tolerated in high risk patients 
often have attractive cost-effectiveness ratios regardless of 
their initial costs. These same interventions may have much 
less favorable cost-effectiveness ratios when applied in low risk 
populations. These findings demonstrate the importance ofthe 
goal of this Bethesda Conference. 
We thank Thomas Lee, MD and Joel Kupersmith, MD for special contributions 
during this conference. 
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Task Force 7. Evaluation and Management of Risk Factors for the 
Individual Patient (Case Management) 
H. J. C SWAN, MD, PHD, FACC, CHAIR,  BERNARD J. GERSH, MB, CHB, DPHIL, FRCP, FACC, 
THOMAS B. GRABOYS, MD, FACC, DANIEL J. ULLYOT, MD, FACC 
Several factors that increase risk for atherosclerosis n general, 
and coronary disease in particular, have been identified and 
are generally accepted in medical practice as valid and relevant 
(1). These include cigarette smoking, sedentary life-style, 
hypertension, abnormal blood lipid levels and a thrombogenic 
tendency, among others. However, conclusive evidence from 
population-based studies of reduction of all-cause mortality by 
modification of such risk factors has been lacking (2-4). 
Nevertheless, ignificant (although modest) reduction in coro- 
nary artery disease (CAD) mortality and morbidity has been 
found in these population studies. This benefit is greatest in 
patients with evidence of coronary disease, or in studies in 
which the control subjects are at a mortality risk of 4% or 
greater per year (5,6). 
The term prevention--"primary" or "secondary"--is widely 
used to encompass reduction of these common risk factors in 
normal persons or in patients with coronary heart disease, 
respectively. "Primary prevention" implies becoming a non- 
smoker, maintaining a normal blood pressure and a desirable 
body weight and consuming no more than 10% of calories 
from saturated fat. In these healthy people, behavior modifi- 
cation, diet and exercise programs are designed to promote a 
healthy life-style. Also, these measures will allow some people 
to avoid or delay the development of atherosclerosis. "Second- 
ary prevention" relates to the treatment of coronary artery 
disease in patients who have had a clinical event (for example, 
angina pectoris or acute myocardial infarction) by reduction of 
conventional risk factors but also includes the use of cardio- 
